N. Luheshi

发表

The Dynamics and Mechanisms of Interleukin-1α and β Nuclear Import

N. Rothwell, D. Brough, N. Luheshi, 2008, Traffic.

Nuclear retention of IL‐1α by necrotic cells: A mechanism to dampen sterile inflammation

B. McColl, D. Brough, N. Luheshi, 2009, European journal of immunology.

Interleukin-1α expression precedes IL-1β after ischemic brain injury and is localised to areas of focal neuronal loss and penumbral tissues

G. López-Castejón, D. Brough, K. Kovács, 2011, Journal of Neuroinflammation.

Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding

Herren Wu, N. Luheshi, Nurten Beyaz, 2015, mAbs.

Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model

R. Wilkinson, N. Luheshi, A. Lewis, 2016, Oncotarget.

Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer

J. Hood, R. Wilkinson, N. Luheshi, 2021, mAbs.

The three cytokines IL-1β, IL-18, and IL-1α share related but distinct secretory routes

G. López-Castejón, D. Brough, P. Kaldis, 2019, The Journal of Biological Chemistry.

Nuclear retention of IL-1 alpha by necrotic cells: A mechanism to dampen sterile inflammation

B. McColl, D. Brough, N. Luheshi, 2018 .

Understanding the influence of the tumor microenvironment on macrophage responses to CD40 agonists

N. Luheshi, G. Davies, J. Legg, 2014, Oncoimmunology.

Boron-Based Inhibitors of the NLRP3 Inflammasome

N. Rothwell, D. Brough, S. Allan, 2017, Cell chemical biology.

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

R. Wilkinson, Z. Cooper, N. Luheshi, 2019, Journal of Immunotherapy for Cancer.

Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment

J. Lapointe, J. Frederick, R. Wilkinson, 2020, Clinical Cancer Research.

Deubiquitinases Regulate the Activity of Caspase-1 and Interleukin-1β Secretion via Assembly of the Inflammasome

G. López-Castejón, D. Brough, S. High, 2012, The Journal of Biological Chemistry.

An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition

K. Flaherty, Dennie T. Frederick, J. Wargo, 2017, The Journal of experimental medicine.

Th1 cytokines are more effective than Th2 cytokines at licensing anti‐tumour functions in CD40‐activated human macrophages in vitro

James Legg, N. Luheshi, M. Mccourt, 2014, European journal of immunology.

First-in-human study of the B7-H4 antibody-drug conjugate (ADC) AZD8205 in patients with advanced/metastatic solid tumors.

Toshio Shimizu, F. Meric-Bernstam, M. Rebelatto, 2022, Journal of Clinical Oncology.

Sphingosine regulates the NLRP3-inflammasome and IL-1β release from macrophages

G. López-Castejón, D. Brough, N. Luheshi, 2011, European journal of immunology.

Boron-Based Inhibitors of the NLRP 3 Inflammasome Graphical Abstract Highlights

N. Rothwell, D. Brough, S. Allan, 2022 .

Structural and functional characterization of C0021158, a high-affinity monoclonal antibody that inhibits Arginase 2 function via a novel non-competitive mechanism of action

V. Cerundolo, M. Carr, M. Barnard, 2020, mAbs.

190P Combination of IPH5201, a blocking antibody targeting the CD39 immunosuppressive pathway, with durvalumab and chemotherapies: Preclinical rationale

J. Lapointe, Z. Cooper, N. Luheshi, 2022, Immuno-Oncology and Technology.

Zinc depletion regulates the processing and secretion of IL-1β

P. Mendes, J. Pahle, G. López-Castejón, 2014, Cell Death and Disease.

Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305.

M. Albertella, Z. Cooper, R. Christie, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Dual functionality of interleukin-1 family cytokines: implications for anti-interleukin-1 therapy

D. Brough, N. Luheshi, N. Luheshi, 2009, British journal of pharmacology.

The three cytokines IL-1 (cid:2) , IL-18, and IL-1 (cid:3) share related but distinct secretory routes

G. López-Castejón, D. Brough, P. Kaldis, 2019 .